Abstract
Purpose
Although cancer diagnosed during pregnancy is rare, the coexistence of pregnancy and malignancy becomes more common in view of prolongation of reproductive age. Therefore, it is important that the specificity of a tumor marker be evaluated during pregnancy to avoid misinterpretation in the follow-up of a pregnant cancer patient. The present study aims to investigate the serum concentrations of CA-125, CA 15-3, CA 19-9 and CEA in healthy pregnant women through gestation.
Methods
In this prospective study, we followed thirty healthy pregnant women. Blood samples were obtained during each trimester of pregnancy (10–12, 22–24 and 34–36 weeks). The maternal serum levels of CA-125, CA 15-3, CA 19-9 and CEA were measured using electrochemiluminescence immunoassay.
Results
There was no difference between the first and second trimester serum levels of CA 125, CEA and CA 19-9. However, serum CA 125 levels in third trimester were found to be significantly elevated in pregnants compared to the second trimester (median values 19.6 vs. 15.6 IU/mL, p = 0,009). Similarly, the serum CEA levels in third trimester were significantly higher than those of second trimester (median values 1.1 vs. 0.7 ng/ml, p = 0.001). It is also found that CEA and CA 19-9 assay values were significantly elevated in the third trimester of pregnancy when compared with the first trimester of pregnancy (CEA median values 1.1 vs. 0.7 ng/ml, p = 0.02 and CA 19-9 median values 11.6 vs. 7.7 IU/mL, p = 0,02). Three trimester had statistically similar levels for serum CA 15-3 (median values 17.5, 19.7 and 18.3 U/mL, respectively). The four tumor markers assay values were found generally within the normal range.
Conclusions
These findings suggest that maternal serum levels of CA 125, CEA and CA 19-9 were increased during third trimester of pregnancy. However, these elevations were within the normal range. CA 15-3 is independent of gestation and reliable tumor markers in monitoring malignancy in pregnant patients.
Similar content being viewed by others
References
Sarandakou A, Protonotariou E, Rizos D (2007) Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 44(2):151–178
Schlageter MH, Larghero J, Cassinat B, Toubert ME, Borschneck C, Rain JD (1998) Serum Carcinoembryonic Antigen, Cancer Antigen 125, Cancer Antigen 15–3, Squamous Cell Carcinoma, and Tumor-associated Trypsin Inhibitor Concentrations during Healthy Pregnancy. Clin Chem 44(9):1995–1998
Cheli CD, Morris DL, Neaman IE, Dai J, Allard WJ, Yeung KK (1999) Measurement of four tumor marker antigens in the sera of pregnant women. J Clin Lab Anal 13(1):35–39
Keinan-Boker L, Lerner-Geva L, Kaufman B, Meirow D (2008) Pregnancy-Associated Breast Cancer. Isr Med Assoc J 10:722–727
Pentheroudakis G (2008) Cancer and pregnancy. Ann Oncol. 19:38–39
Høgdall E (2008) Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 20:4–8
Stuırgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48(8):1151–1159
Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52(3):345–351
Fry LC, Mönkemüller K, Malfertheiner P (2008) Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 393:883–890
Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33(3):266–270
Duffy MJ (2001) Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 47(4):624–630
Touitou Y, Darbois Y, Bogdan A, Auzeby A, Keusseoglou S (1989) Tumour marker antigens during menses and pregnancy. Br J Cancer 60(3):419–420
Bon GG, Kenemans P, Verstraeten AA, Go S, Philipi PA, van Kamp GJ, van Geijn HP, van Vugt JM (2001) Maternal serum Ca125 and Ca15–3 antigen levels in normal and pathological pregnancy. Fetal Diagn 16(3):166–172
Kobayashi F, Sagawa N, Nakamura K, Nonogaki M, Ban C, Fujii S, Mori T (1989) Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women. Am J Obstet Gynecol 160(3):563–566
Spitzer M, Kaushal N, Benjamin F (1998) Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 43(4):387–392
Botsis D, Sarandakou A, Kassanos D, Kontoravdis A, Rizos D, Protonotariou E, Phocas I, Creatsas G (1999) Breast cancer markers during normal pregnancy. Anticancer Res 19(4C):3539–3541
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ercan, Ş., Kaymaz, Ö., Yücel, N. et al. Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study. Arch Gynecol Obstet 285, 579–584 (2012). https://doi.org/10.1007/s00404-011-2025-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-011-2025-4